Emgality ® (galkanezumab)

För fullständig produktresumé för Emgality® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Emgality® ▼ (galcanezumab): Skydd mot Ljus

Medicinen skall förvaras i originalförpackningen för att skyddas mot ljus.

Additional Information

The medicine in the device should be protected from all types of light (i.e. artificial indoor light, filtered daylight or outdoor lighting).1

It is acceptable to expose the solution in the device to indoor light “artificial or filtered daylight” when the dose is taken/administered.1

If the original package is not available, then the device should be protected from light.1

The device should be stored in the original package in the refrigerator (2 °C to 8 °C) until it is time to use the medicine. The package protects the device from light and helps to keep the device safe from accidental damage.1

The instructions for using the pen or syringe included with the Package Leaflet, must be followed carefully. The pre-filled pen and pre-filled syringe is for total use only.2,3

After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate. 2

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3. Emgality [package leaflet]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M02 15


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss